Trevena Investor Relations Material
Latest events
Q3 2023
Trevena
Q3 2024
7 Nov, 2024
Q2 2024
8 Aug, 2024
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Trevena Inc
Access all reports
Trevena Inc. is a biopharmaceutical company focused on developing and commercializing innovative medicines targeted at central nervous system (CNS) disorders. The company's portfolio includes OLINVYK (oliceridine) injection, which is approved for use in adults to manage acute pain severe enough to require an intravenous opioid analgesic when alternative treatments are inadequate. Trevena also has several investigational drug candidates in its pipeline. The company is headquartered in Chesterbrook, Pennsylvania, and its shares are listed on the NASDAQ.
Latest articles
)
Eli Lilly: The Pharma Giant Behind Mounjaro and Zepbound
Eli Lilly's journey from insulin pioneer to global pharma giant, leading innovation in diabetes, obesity, and the future of metabolic health.
30 Jun 2025
)
500 Years of Craft, One Family Legacy: Beretta Holding's Global Expansion
How Beretta Holding managed to transform from a 16th-century gun barrel producer into a global industrial group while preserving 500 years of legacy.
27 Jun 2025
)
Shuntaro Furukawa: The Sixth President of Nintendo
Shuntaro Furukawa, Nintendo's sixth president, went from a childhood fan to leading the company through global expansion and the launch of Switch 2.
23 Jun 2025
Ticker symbol
TRVN
Country
🇺🇸 United States